Indivior Pharmaceuticals, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Indivior Pharmaceuticals (≈$1.8B market cap) and Supernus Pharmaceuticals are merging in a 100% stock-for-stock transaction with an exchange ratio of 1.5401 Indivior shares per Supernus share. Indivior will distribute a $1B dividend to pre-closing shareholders; post-close ownership is 56.5% Indivior and 43.5% Supernus. The combined entity targets $2.2B LTM net revenue (as of 6/30/26), $888M adjusted EBITDA, and at least $125M in annual cost synergies, with close targeted for Q4 2026.
Why this rating
Transformational merger creating $2.2B CNS leader (≈122% of Indivior's current market cap), $125M synergies (~14% of combined EBITDA), $1B special dividend, and substantial scale for future M&A. Major strategic and financial restructuring relative to company size.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.